News articles about Fluidigm (NASDAQ:FLDM) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Fluidigm earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.0817677797082 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Separately, ValuEngine cut Fluidigm from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th.

Fluidigm (NASDAQ:FLDM) traded up $0.34 during trading on Wednesday, reaching $6.23. The company’s stock had a trading volume of 131,400 shares, compared to its average volume of 149,350. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02. The firm has a market cap of $245.80, a PE ratio of -2.79 and a beta of 3.37. Fluidigm has a 12-month low of $2.52 and a 12-month high of $8.69.

In other news, insider Levin Capital Strategies, L.P. purchased 11,230 shares of the business’s stock in a transaction on Friday, December 29th. The stock was purchased at an average price of $5.94 per share, with a total value of $66,706.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last ninety days, insiders acquired 548,306 shares of company stock valued at $2,709,439. Insiders own 4.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Fluidigm (FLDM) Receiving Somewhat Favorable Press Coverage, Report Finds” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with Analyst Ratings Network's FREE daily email newsletter.